Brief: InDex Pharmaceuticals Q1 EBIT Loss at SEK 44.3 Million
24/05/2023 07:03
May 24 (Reuters) - InDex Pharmaceuticals Q1 cash flow from operating activities SEK -23.1 million. * Q1 sales SEK 0 * Q1 net income SEK -41.8 million * Q1 EBIT SEK -44.3 million
Recent news on Flerie AB
See all newsBrief: Flerie Q3 Net Asset Value SEK 3,113 Million
Brief: Flerie Portfolio Co Reports Positive Data From Clinical Proof-Of-Mechanism Study
Brief: Flerie Writes Down Value Of Holding In Empros Pharma
Brief: Nasdaq Approves Biosergen's Delisting Application
Brief: Flerie Approves Merger Plan For Flerie And Biosergen